Mattson R H, Cramer J A, Collins J F
Neurosurgery Service, Veterans Affairs Medical Center, West Haven, CT 06516-2700.
N Engl J Med. 1992 Sep 10;327(11):765-71. doi: 10.1056/NEJM199209103271104.
Valproate is approved for use primarily in patients with absence seizures, but the drug has a broad spectrum of activity against seizures of all types. Partial or secondarily generalized tonic-clonic seizures are often difficult to control adequately with standard treatment, usually carbamazepine or phenytoin.
We conducted a multicenter, double-blind trial that compared valproate with carbamazepine in the treatment of 480 adults with complex partial seizures (206 patients) or secondarily generalized tonic-clonic seizures (274 patients). The patients were randomly assigned to treatment with carbamazepine or divalproex sodium (valproate) at doses adjusted to achieve blood levels in the middle of the therapeutic range. Patients were followed for one to five years or until seizures became uncontrollable, treatment had unacceptable adverse effects, or both these events occurred.
For the control of secondarily generalized tonic-clonic seizures, carbamazepine and valproate were comparably effective (in 136 patients and 138 patients, respectively). For complex partial seizures, four of five outcome measures favored carbamazepine (100 patients) over valproate (106 patients): the total number of seizures (2.7 vs. 7.6, P = 0.05), the number of seizures per month (0.9 vs. 2.2, P = 0.01), the time to the first seizure (P less than 0.02), and the seizure-rating score (P = 0.04). Carbamazepine was also superior according to a composite score that combined scores for the control of seizures and for adverse effects (P less than 0.001). Valproate was associated more frequently than carbamazepine with a weight gain of more than 5.5 kg (12 lb) (20 percent vs. 8 percent, P less than 0.001), with hair loss or change in texture (12 percent vs. 6 percent, P = 0.02), and with tremor (45 percent vs. 22 percent, P less than 0.001). Rash was more often associated with carbamazepine (11 percent vs. 1 percent, P less than 0.001).
Valproate is as effective as carbamazepine for the treatment of generalized tonic-clonic seizures, but carbamazepine provides better control of complex partial seizures and has fewer long-term adverse effects.
丙戊酸盐主要被批准用于失神发作患者,但该药物对所有类型的癫痫发作都有广泛的活性。部分性或继发性全身性强直阵挛性发作通常难以通过标准治疗(通常是卡马西平或苯妥英钠)得到充分控制。
我们进行了一项多中心、双盲试验,比较丙戊酸盐与卡马西平治疗480例成人复杂部分性发作(206例患者)或继发性全身性强直阵挛性发作(274例患者)的疗效。患者被随机分配接受卡马西平或丙戊酸钠(丙戊酸盐)治疗,剂量根据治疗范围中间的血药浓度进行调整。对患者进行一至五年的随访,或直至癫痫发作无法控制、治疗出现不可接受的不良反应,或上述两种情况均发生。
对于继发性全身性强直阵挛性发作的控制,卡马西平和丙戊酸盐的疗效相当(分别为136例患者和138例患者)。对于复杂部分性发作,五项结局指标中的四项显示卡马西平(100例患者)优于丙戊酸盐(106例患者):癫痫发作总数(2.7次对7.6次,P = 0.05)、每月癫痫发作次数(0.9次对2.2次,P = 0.01)、首次癫痫发作时间(P < 0.02)和癫痫发作评分(P = 0.04)。根据综合评分(结合癫痫发作控制评分和不良反应评分),卡马西平也更具优势(P < 0.001)。与卡马西平相比,丙戊酸盐更常与体重增加超过5.5千克(12磅)相关(20%对8%,P < 0.001)、与脱发或发质改变相关(12%对6%,P = 0.02)以及与震颤相关(45%对22%,P < 0.001)。皮疹更常与卡马西平相关(11%对1%,P < 0.001)。
丙戊酸盐在治疗全身性强直阵挛性发作方面与卡马西平疗效相当,但卡马西平对复杂部分性发作的控制更好,且长期不良反应更少。